Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP956400.RAofEBwWzTIg8uJCtfzrAVcIHs78pZbjSqNoEeJO-lfgI130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP956400.RAofEBwWzTIg8uJCtfzrAVcIHs78pZbjSqNoEeJO-lfgI130_assertion type Assertion NP956400.RAofEBwWzTIg8uJCtfzrAVcIHs78pZbjSqNoEeJO-lfgI130_head.
- NP956400.RAofEBwWzTIg8uJCtfzrAVcIHs78pZbjSqNoEeJO-lfgI130_assertion description "[Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive nonsmall cell lung cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP956400.RAofEBwWzTIg8uJCtfzrAVcIHs78pZbjSqNoEeJO-lfgI130_provenance.
- NP956400.RAofEBwWzTIg8uJCtfzrAVcIHs78pZbjSqNoEeJO-lfgI130_assertion evidence source_evidence_literature NP956400.RAofEBwWzTIg8uJCtfzrAVcIHs78pZbjSqNoEeJO-lfgI130_provenance.
- NP956400.RAofEBwWzTIg8uJCtfzrAVcIHs78pZbjSqNoEeJO-lfgI130_assertion SIO_000772 22282074 NP956400.RAofEBwWzTIg8uJCtfzrAVcIHs78pZbjSqNoEeJO-lfgI130_provenance.
- NP956400.RAofEBwWzTIg8uJCtfzrAVcIHs78pZbjSqNoEeJO-lfgI130_assertion wasDerivedFrom befree-2016 NP956400.RAofEBwWzTIg8uJCtfzrAVcIHs78pZbjSqNoEeJO-lfgI130_provenance.
- NP956400.RAofEBwWzTIg8uJCtfzrAVcIHs78pZbjSqNoEeJO-lfgI130_assertion wasGeneratedBy ECO_0000203 NP956400.RAofEBwWzTIg8uJCtfzrAVcIHs78pZbjSqNoEeJO-lfgI130_provenance.